Regulations and Regulatory Issues

Latest News


Psychedelics, also known as entheogens. Everyone has an opinion. From the superb kaleidoscope shapes, or making that concert even more memorable, or to digging a bit deeper within yourself for self-healing—entheogens can be a game changer. For some, these experiences are life changing, especially if it means improving well-being and life satisfaction. Thanks to many published clinical trials, the benefits of using entheogens such as psilocybin include reducing anxiety and depression, successful addiction interruption, post-traumatic stress disorder (PTSD) treatment, and many others. With increased awareness of the benefits of psilocybin and other entheogens, we are observing an acceptance of entheogens followed by decriminalization and future legalization.

Cannabis testing laboratories play an important role in ensuring consumer safety and quality throughout the industry. These laboratories face many challenges—from the variety of samples in the industry to changing regulations and testing requirements and everything in between. In this interview, Sarah Ahrens, Founder and CEO of True Labs for Cannabis LLC, explains her philosophy and approach behind building her cannabis analytical testing laboratory in New Jersey. She also covers current developments in the cannabis testing industry and what needs to be done to ensure it has a transparent and productive future that benefits producers and consumers alike.

Delta-8 and delta-10 have gained considerable traction over the past year. Although these cannabinoid isomers fall in an extreme grey area, consumers are driving up demand. They can be purchased in many different forms and are commonly found in vaping products, gummies, and tinctures. Since these isomers are commonly derived from hemp extract, many consumers see delta-8 and delta-10 as a lawful hemp-derived good that provides a psychoactive effect. Per a new stance from the federal government, vaping products with these isomers fall under the 2018 Farm Bill. Even with the Food and Drug Administration’s (FDA) stance regarding the 2018 Farm Bill exempting hemp from the Controlled Substances Act (CSA), the popular edible cannabinoid isomers are not automatically legal.

In the cannabis industry there seems to be a misconception that your company will never have a recall in its lifetime, or that there isn’t any possibility it will ever happen to you. In reality, all cannabis companies experience at least one or multiple recalls during their lifetime. It isn’t about if it will happen, it’s more of a when. And when it happens, how will your company handle it?

Regulations and compliance are sometimes deemed a necessary evil, but consumer and employee safety are at the heart of those rules. The cannabis industry faces unique challenges when it comes to compliance because each state has their own rules. Federal regulation would certainly simplify matters, but until then Kim Stuck, CEO and founder of Allay Consulting, offers some practical advice for how to stay ahead of potential issues. Here, Stuck shares her background in regulatory work, the cannabis industry, her new blog coming out in Cannabis Science and Technology next month, and more.

The COVID-19 pandemic affected all types of businesses, such as those found in the cannabis industry. Though it was hit hard from the virus, the cannabis industry suffered another blow in the form of the December 2020 COVID-19 stimulus package, which included a provision classifying all vape products as cigarettes, subjecting them to the same regulations as cigarettes. Here, U.S. Navy veteran Dana E. Shoched, president and chief executive officer of O2VAPE, discusses the impacts this legislation may have on the cannabis vaping industry.